Financial Performance - GeneDx grew revenues to $87.1 million, a 42% increase year-over-year[4] - Exome and genome test revenue grew to $71.4 million, a 62% increase year-over-year, representing 40% of all test results[4,9] - The company delivered an adjusted gross margin of 69%, up from 61% in the first quarter of 2024[4] - Adjusted net income for the first quarter of 2025 was $7.7 million[4,13] - Cash, cash equivalents, marketable securities, and restricted cash totaled $160.2 million as of March 31, 2025[13] Guidance and Acquisition - Full year 2025 revenue is projected to be between $360 million and $375 million, including $3 million to $5 million from the Fabric Genomics acquisition[5] - Exome/genome volume and revenue growth is expected to be at least 30%[5] - Adjusted gross margins are projected to be between 66% and 68%[5] - GeneDx announced plans to acquire Fabric Genomics, with the deal expected to close in Q2 2025, for an upfront purchase price of $33 million, potentially reaching $51 million in total consideration[4,30] Market and Strategy - GeneDx has contracted with 80% of covered lives, including all large national commercial payers[58,65,82] - The company estimates a $45 billion total market opportunity for exome/genome use cases, with $25 billion in pediatrics and rare diseases and $20 billion in adult applications[56] - GeneDx has screened 17,000 healthy infants with genome sequencing in the GUARDIAN study, with a goal of >100,000[80]